AR042051A1 - Tratamiento combinado contra el cancer con un compuesto anti-cancerigeno activado por glutationa s- transferasa (gst) y otro tratamiento contra el cancer - Google Patents

Tratamiento combinado contra el cancer con un compuesto anti-cancerigeno activado por glutationa s- transferasa (gst) y otro tratamiento contra el cancer

Info

Publication number
AR042051A1
AR042051A1 ARP030104215A ARP030104215A AR042051A1 AR 042051 A1 AR042051 A1 AR 042051A1 AR P030104215 A ARP030104215 A AR P030104215A AR P030104215 A ARP030104215 A AR P030104215A AR 042051 A1 AR042051 A1 AR 042051A1
Authority
AR
Argentina
Prior art keywords
against cancer
treatment against
gst
glutationa
cancerigene
Prior art date
Application number
ARP030104215A
Other languages
English (en)
Spanish (es)
Original Assignee
Telik Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Telik Inc filed Critical Telik Inc
Publication of AR042051A1 publication Critical patent/AR042051A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ARP030104215A 2002-11-15 2003-11-14 Tratamiento combinado contra el cancer con un compuesto anti-cancerigeno activado por glutationa s- transferasa (gst) y otro tratamiento contra el cancer AR042051A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42698302P 2002-11-15 2002-11-15

Publications (1)

Publication Number Publication Date
AR042051A1 true AR042051A1 (es) 2005-06-08

Family

ID=32326463

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030104215A AR042051A1 (es) 2002-11-15 2003-11-14 Tratamiento combinado contra el cancer con un compuesto anti-cancerigeno activado por glutationa s- transferasa (gst) y otro tratamiento contra el cancer

Country Status (12)

Country Link
US (2) US20040138140A1 (https=)
EP (1) EP1562564A2 (https=)
JP (2) JP2006508980A (https=)
KR (1) KR20050075018A (https=)
CN (2) CN101590229B (https=)
AR (1) AR042051A1 (https=)
AU (2) AU2003290805A1 (https=)
BR (1) BR0316364A (https=)
CA (1) CA2505377A1 (https=)
MX (1) MXPA05005200A (https=)
TW (1) TWI323662B (https=)
WO (1) WO2004045593A2 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0011903D0 (en) * 2000-05-18 2000-07-05 Astrazeneca Ab Combination chemotherapy
TW200538149A (en) * 2004-05-20 2005-12-01 Telik Inc Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound
JP5371426B2 (ja) * 2004-07-09 2013-12-18 プロルックス ファーマシューティカルズ コープ． ワートマニン類似体及び化学療法薬と組み合わせた同一物を使用する方法
EP1833978B1 (en) * 2005-01-06 2008-10-08 Telik, Inc. Tripeptide and tetrapeptide thioethers
US8178564B2 (en) 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168661B2 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US20110033528A1 (en) * 2009-08-05 2011-02-10 Poniard Pharmaceuticals, Inc. Stabilized picoplatin oral dosage form
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
US20100260832A1 (en) * 2007-06-27 2010-10-14 Poniard Pharmaceuticals, Inc. Combination therapy for ovarian cancer
US20100310661A1 (en) * 2007-07-16 2010-12-09 Poniard Pharmaceuticals, Inc. Oral formulations for picoplatin
HRP20160625T1 (hr) 2007-09-10 2016-08-12 Boston Biomedical, Inc. Novi inhibitori stat3 signalnog puta i inhibitori matičnih stanica raka
CA2715348A1 (en) * 2008-02-08 2009-08-13 Poniard Pharmaceuticals, Inc. Use of picoplatin and bevacizumab to treat colorectal cancer
US20110021618A1 (en) * 2008-03-25 2011-01-27 Paloma Pharmaceuticals, Inc. Methods of treating fibrotic disorders
WO2010086964A1 (ja) * 2009-01-28 2010-08-05 株式会社 静岡カフェイン工業所 がん治療のための併用療法
EP2425830A1 (en) * 2010-09-03 2012-03-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synergistic drug combination for the treatment of cancer
US20140296178A1 (en) * 2010-12-01 2014-10-02 Niiki Pharma Acquisition Corp. 2 Combination Therapy with a Gallium Complex
US9381187B2 (en) 2011-02-16 2016-07-05 Paloma Pharmaceuticals, Inc. Radiation countermeasure agents
US20120251496A1 (en) * 2011-03-31 2012-10-04 Telik, Inc. Ezatiostat for treating multiple myeloma
CA2908380A1 (en) 2013-04-09 2014-10-16 Boston Biomedical, Inc. Methods for treating cancer
US20170080093A1 (en) * 2013-10-22 2017-03-23 Tyme, Inc. Tyrosine Derivatives And Compositions Comprising Them
BR112017000800A8 (pt) * 2014-07-17 2023-04-25 Biocurity Holdings Inc Tratamento do câncer com uma combinação de radiação, nanoparticulas de óxido de cério, e um agente quimioterápico
US11389536B2 (en) 2015-07-17 2022-07-19 BioCurity Pharmaceuticals Inc. Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent
WO2018102427A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
AU2017368135A1 (en) * 2016-11-30 2019-06-13 Tyme, Inc. Tyrosine derivatives and compositions comprising them
WO2018213424A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer
CN115768967B (zh) * 2020-09-28 2025-07-11 三菱重工业株式会社 蒸汽涡轮
WO2023101359A1 (ko) * 2021-11-30 2023-06-08 광주과학기술원 Pip4k2c 억제제를 유효성분으로 포함하는 암 치료용 조성물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5599903A (en) * 1992-04-03 1997-02-04 Terrapin Technologies, Inc. Glutathione analogs and paralog panels comprising glutathione mimics
US5545621A (en) * 1991-04-29 1996-08-13 Terrapin Technologies, Inc. Glutathione S-transferase-activated compounds
US5556942A (en) * 1991-04-29 1996-09-17 Terrapin Technologies, Inc. Glutathione S-transferase-activated compounds
US5955432A (en) * 1992-04-03 1999-09-21 Terrapin Technologies, Inc. Metabolic effects of certain glutathione analogs
US5767147A (en) * 1995-04-21 1998-06-16 The Regents Of The University Of California Inhibition of glutathione transferase by haloenol lactones
DK0831877T3 (da) * 1995-06-07 2005-02-14 Telik Inc Metabolske virkninger af visse glutathionanaloge
US5880097A (en) * 1996-01-04 1999-03-09 Terrapin Techologies, Inc. Tethered prodrugs
US20030073837A1 (en) * 1998-12-31 2003-04-17 Langecker Peter J. 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy
US6281223B1 (en) * 1999-04-13 2001-08-28 Supergen, Inc. Radioenhanced camptothecin derivative cancer treatments
GB9909925D0 (en) * 1999-04-29 1999-06-30 Pharmacia & Upjohn Spa Combined preparations comprising anthracycline derivatives
JP2003522790A (ja) * 2000-02-17 2003-07-29 メルク エンド カムパニー インコーポレーテッド Ｃｏｘ−２選択的阻害薬を用いた前立腺癌の治療または予防
AU2002246827B2 (en) * 2000-12-22 2008-02-21 Bristol-Myers Squibb Company Methods for modulating tumor growth and metastasis
TW200538149A (en) * 2004-05-20 2005-12-01 Telik Inc Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound

Also Published As

Publication number Publication date
US20040138140A1 (en) 2004-07-15
CN101590229A (zh) 2009-12-02
WO2004045593A2 (en) 2004-06-03
TW200412933A (en) 2004-08-01
CN1711076A (zh) 2005-12-21
TWI323662B (en) 2010-04-21
CN101590229B (zh) 2012-12-05
CA2505377A1 (en) 2004-06-03
JP2006508980A (ja) 2006-03-16
BR0316364A (pt) 2005-10-04
US20080159980A1 (en) 2008-07-03
KR20050075018A (ko) 2005-07-19
AU2010200483A1 (en) 2010-03-04
EP1562564A2 (en) 2005-08-17
CN100508961C (zh) 2009-07-08
JP2010265305A (ja) 2010-11-25
WO2004045593A3 (en) 2004-08-12
AU2003290805A1 (en) 2004-06-15
MXPA05005200A (es) 2005-08-18

Similar Documents

Publication Publication Date Title
AR042051A1 (es) Tratamiento combinado contra el cancer con un compuesto anti-cancerigeno activado por glutationa s- transferasa (gst) y otro tratamiento contra el cancer
PE20060002A1 (es) Combinaciones antineoplasicas de cci-779 y rituximab
CR7575A (es) Uso de docetaxel/doxorrubicina/ciclofosfamida en la terapia adyuvante de cancer de mama y ovario
CO5700796A2 (es) Composiciones que contienen piperacilina y tazobactam utiles para inyecciones
ES2109899T1 (es) Metodo, composiciones y kits para aumentar la biodisponibilidad oral de agentes farmaceuticos.
AR023806A1 (es) Uso de una mezcla de peptidos para la manufactura de un agente terapeutico para la profilaxis y/o el tratamiento del cancer, las composicionesfarmaceuticas y vacunas que contienen dicha mezcla y los procedimientos de preparacion de dichas composiciones y vacunas
ES2421516T3 (es) Composiciones para tratar el cáncer usando el inhibidor de proteasomas PS-341
UY27943A1 (es) Composiciones y mctodos para tratar el crncer usando inmunoconjugados de anticuerpo para cd44 citotnxicos y agentes quimioterapcuticos
ECSP056159A (es) Composición de fármaco conjugado
ES2172944T3 (es) Forma de dosificacion osmotica que comprende un primer y un segundo revestimiento.
UY27296A1 (es) Composición farmacéutica que contiene mosaprida y pancreatina
AR109263A2 (es) Composición que comprende moxidectina
BRPI0515645A (pt) métodos terapêuticos, composições, compostos e usos de compostos
AR034813A1 (es) Composiciones farmaceuticas y uso de las mismas
AR006401A1 (es) Compuestos de pirrolopirrolona, una composicion farmaceutica que los contiene, su uso en la fabricacion de un medicamento y en terapia, procesospara su preparación y compuestos intermediarios para dichos procesos.
SI1680128T1 (sl) Mio-inozitol heksafosfat za topično uporabo
CO2022015428A2 (es) Compuesto de oxofenilarsina deuterada y uso del mismo
UY26171A1 (es) Método y formulación farmacéutica para el tratamiento de la discinesia de aparición tardía
EA200100568A1 (ru) Фармацевтические композиции в капсулах из гидроксипропилметилцеллюлозы
MXPA04001398A (es) Metodo para el tratamiento y prevencion de dolor e inflamacion con glucosamina y un inhibidor selectivo de ciclooxigenasa-2 y composiciones para el mismo.
AR052830A1 (es) Regimen de cladribina para tratar esclerosis multiple
AR046853A1 (es) Mezclas insecticidas que contienen triflumuron con actividad sinergica
CO5700723A2 (es) Uso de un derivado de amina ciclica especifico o de sus sales farmaceuticamente aceptables para tratar y prevenir la insuficiencia cardiaca
AR034142A1 (es) Una composicion farmaceutica, metodo para fabricar un medicamento en base a dicha composicion y uso de la composicion
AR003434A1 (es) Compuesto de tiludronato, composiciones farmaceuticas que los contienen y proceso para producir dicho compuesto y procedimiento para producir lascomposiciones farmaceuticas.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal